First German Hospital Pilots Steriwave

Ondine Biomedical Partners with LMU University Hospital Munich
 to Trial Steriwave in ENT Patients

Ondine Biomedical Inc. is pleased to announce a significant research collaboration with LMU University Hospital Munich, one of Europe’s most esteemed and highly ranked medical institutions. This partnership marks a pivotal step in introducing Ondine’s Steriwave® photodisinfection technology to Germany, the European Union, and other major international markets, underscoring the growing importance of innovative infection prevention solutions in global healthcare.

The collaborative research initiative will be led by Professor Dr. Ronald Sroka, Head of the LIFE Center and Laser Research Laboratory at LMU University Hospital Munich, along with PD Dr. Veronika Volgger, Clinical Scientist at LIFE Center and Department of ENT at LMU University Hospital Munich. Renowned for its excellence in biophotonics and photodynamic therapy (PDT), the LIFE Center brings unparalleled expertise to this project, further strengthening the scientific foundation for Steriwave’s clinical evaluation in ENT patients.

This initiative is bolstered by external clinical evidence, including a pilot study presented at the American Rhinologic Society’s 66th Annual Meeting in 2020 by Prof. Claire Hopkins, consultant ENT surgeon at Guy’s & St Thomas Hospital and London Bridge Hospital, and her team. Their findings demonstrated that routine pre-operative nasal photodisinfection significantly reduced the need for post-operative antibiotics in sinonasal surgery patients, with prescription rates dropping from 22.5% to 5% (P=0.02), highlighting the technology’s potential to combat healthcare-associated infections and antimicrobial resistance.

Professor Dr. Ronald Sroka commented:

“Innovative solutions are more vital than ever in the fight against antibiotic resistance. Our team at LMU is deeply committed to advancing photodynamic approaches that address the growing threat of antimicrobial resistance. Ondine’s Steriwave represents a promising, non-antibiotic strategy to reduce multidrug-resistant infections, and we are delighted to bring our clinical expertise to validate this important technology and help reduce unnecessary post-surgical infections.”

Carolyn Cross, CEO of Ondine Biomedical Inc., stated:

“We are truly honoured to partner with the outstanding and visionary team at LMU University Hospital Munich. Their leadership in photodynamic therapy and commitment to scientific excellence make them the ideal collaborators as we introduce our innovative photodisinfection technology to Germany, the EU, and key global markets. This collaboration reflects our shared dedication to combating antibiotic resistance and delivering safe, effective infection prevention solutions that can transform patient care and outcomes worldwide.”